Award

NIH Reporter #1R01AI201701-01

Immunomodulatory Blockade of Type 2 Immunity for Severe Coccidioidomycosis

Recipient

University of California Los Angeles (UCLA)

Award Amount

$787,484.00

Ceiling

$787,484.00

Awarded

August 11, 2026

Identifier

1R01AI201701-01

The project will evaluate dupilumab as an add-on treatment for severe Valley fever and assess its effects on immune responses and clinical outcomes.

Description

A prospective, randomized, placebo-controlled, blinded trial testing whether adjunctive dupilumab with standard antifungal medicines improves outcomes for patients with severe coccidioidomycosis and Type 2 immune skewing.

View original record